ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product

by Eddie Staley, Benzinga Editor
June 26, 2012 8:02 AM | 16 seconds read |
ADVENTRX Pharmaceuticals, Inc. ANX today announced that is has entered into a multi-year agreement with Patheon Inc. under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the phase 3 study of ANX-188 that ADVENTRX plans to initiate this year.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsContractsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!